173 related articles for article (PubMed ID: 10400910)
1. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction.
Muthuchamy M; Pieples K; Rethinasamy P; Hoit B; Grupp IL; Boivin GP; Wolska B; Evans C; Solaro RJ; Wieczorek DF
Circ Res; 1999 Jul; 85(1):47-56. PubMed ID: 10400910
[TBL] [Abstract][Full Text] [Related]
2. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity.
Bottinelli R; Coviello DA; Redwood CS; Pellegrino MA; Maron BJ; Spirito P; Watkins H; Reggiani C
Circ Res; 1998 Jan 9-23; 82(1):106-15. PubMed ID: 9440709
[TBL] [Abstract][Full Text] [Related]
3. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.
Rajan S; Ahmed RP; Jagatheesan G; Petrashevskaya N; Boivin GP; Urboniene D; Arteaga GM; Wolska BM; Solaro RJ; Liggett SB; Wieczorek DF
Circ Res; 2007 Jul; 101(2):205-14. PubMed ID: 17556658
[TBL] [Abstract][Full Text] [Related]
4. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade.
Michele DE; Gomez CA; Hong KE; Westfall MV; Metzger JM
Circ Res; 2002 Aug; 91(3):255-62. PubMed ID: 12169652
[TBL] [Abstract][Full Text] [Related]
5. Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis.
Jagatheesan G; Rajan S; Petrashevskaya N; Schwartz A; Boivin G; Arteaga GM; Solaro RJ; Liggett SB; Wieczorek DF
Am J Physiol Heart Circ Physiol; 2007 Aug; 293(2):H949-58. PubMed ID: 17416600
[TBL] [Abstract][Full Text] [Related]
6. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice.
Prabhakar R; Boivin GP; Grupp IL; Hoit B; Arteaga G; Solaro RJ; Wieczorek DF
J Mol Cell Cardiol; 2001 Oct; 33(10):1815-28. PubMed ID: 11603924
[TBL] [Abstract][Full Text] [Related]
7. Changes in end-to-end interactions of tropomyosin affect mouse cardiac muscle dynamics.
Gaffin RD; Gokulan K; Sacchettini JC; Hewett TE; Klevitsky R; Robbins J; Sarin V; Zawieja DC; Meininger GA; Muthuchamy M
Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H552-63. PubMed ID: 16501024
[TBL] [Abstract][Full Text] [Related]
8. Charged residue changes in the carboxy-terminus of alpha-tropomyosin alter mouse cardiac muscle contractility.
Gaffin RD; Gokulan K; Sacchettini JC; Hewett T; Klevitsky R; Robbins J; Muthuchamy M
J Physiol; 2004 Apr; 556(Pt 2):531-43. PubMed ID: 14766940
[TBL] [Abstract][Full Text] [Related]
9. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations.
Coutu P; Bennett CN; Favre EG; Day SM; Metzger JM
Circ Res; 2004 May; 94(9):1235-41. PubMed ID: 15059934
[TBL] [Abstract][Full Text] [Related]
10. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility.
Bing W; Redwood CS; Purcell IF; Esposito G; Watkins H; Marston SB
Biochem Biophys Res Commun; 1997 Jul; 236(3):760-4. PubMed ID: 9245729
[TBL] [Abstract][Full Text] [Related]
11. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes.
Michele DE; Albayya FP; Metzger JM
Nat Med; 1999 Dec; 5(12):1413-7. PubMed ID: 10581085
[TBL] [Abstract][Full Text] [Related]
12. Physiological consequences of tropomyosin mutations associated with cardiac and skeletal myopathies.
Michele DE; Metzger JM
J Mol Med (Berl); 2000; 78(10):543-53. PubMed ID: 11199327
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene.
Coviello DA; Maron BJ; Spirito P; Watkins H; Vosberg HP; Thierfelder L; Schoen FJ; Seidman JG; Seidman CE
J Am Coll Cardiol; 1997 Mar; 29(3):635-40. PubMed ID: 9060904
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy.
Palmiter KA; Solaro RJ
Basic Res Cardiol; 1997; 92 Suppl 1():63-74. PubMed ID: 9202846
[TBL] [Abstract][Full Text] [Related]
15. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy.
Rajan S; Williams SS; Jagatheesan G; Ahmed RP; Fuller-Bicer G; Schwartz A; Aronow BJ; Wieczorek DF
Physiol Genomics; 2006 Nov; 27(3):309-17. PubMed ID: 16882888
[TBL] [Abstract][Full Text] [Related]
16. Charged residue alterations in the inner-core domain and carboxy-terminus of alpha-tropomyosin differentially affect mouse cardiac muscle contractility.
Gaffin RD; Tong CW; Zawieja DC; Hewett TE; Klevitsky R; Robbins J; Muthuchamy M
J Physiol; 2004 Dec; 561(Pt 3):777-91. PubMed ID: 15486021
[TBL] [Abstract][Full Text] [Related]
17. An internal domain of beta-tropomyosin increases myofilament Ca(2+) sensitivity.
Jagatheesan G; Rajan S; Schulz EM; Ahmed RP; Petrashevskaya N; Schwartz A; Boivin GP; Arteaga GM; Wang T; Wang YG; Ashraf M; Liggett SB; Lorenz J; Solaro RJ; Wieczorek DF
Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H181-90. PubMed ID: 19429821
[TBL] [Abstract][Full Text] [Related]
18. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy.
Evans CC; Pena JR; Phillips RM; Muthuchamy M; Wieczorek DF; Solaro RJ; Wolska BM
Am J Physiol Heart Circ Physiol; 2000 Nov; 279(5):H2414-23. PubMed ID: 11045979
[TBL] [Abstract][Full Text] [Related]
19. Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy.
Schulz EM; Wilder T; Chowdhury SA; Sheikh HN; Wolska BM; Solaro RJ; Wieczorek DF
J Biol Chem; 2013 Oct; 288(40):28925-35. PubMed ID: 23960072
[TBL] [Abstract][Full Text] [Related]
20. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis.
Karibe A; Tobacman LS; Strand J; Butters C; Back N; Bachinski LL; Arai AE; Ortiz A; Roberts R; Homsher E; Fananapazir L
Circulation; 2001 Jan; 103(1):65-71. PubMed ID: 11136687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
